Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Buy" from Analysts

Shares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) have been assigned an average recommendation of "Buy" from the eight brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $35.75.

XNCR has been the subject of several recent research reports. Wedbush restated an "outperform" rating and set a $38.00 target price on shares of Xencor in a report on Thursday, November 7th. Royal Bank of Canada upped their target price on Xencor from $31.00 to $34.00 and gave the company an "outperform" rating in a research note on Thursday, September 26th. JPMorgan Chase & Co. increased their target price on Xencor from $27.00 to $28.00 and gave the company an "overweight" rating in a report on Thursday, November 7th. Finally, BMO Capital Markets reissued an "outperform" rating and issued a $34.00 price target (up from $32.00) on shares of Xencor in a report on Friday, November 8th.

Insider Activity

In related news, VP John R. Desjarlais sold 68,684 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $23.48, for a total value of $1,612,700.32. Following the transaction, the vice president now directly owns 200,104 shares of the company's stock, valued at approximately $4,698,441.92. This trade represents a 25.55 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Bassil I. Dahiyat sold 3,366 shares of Xencor stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $24.02, for a total value of $80,851.32. Following the completion of the transaction, the chief executive officer now owns 352,615 shares in the company, valued at $8,469,812.30. The trade was a 0.95 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.23% of the company's stock.

Hedge Funds Weigh In On Xencor

A number of large investors have recently modified their holdings of the company. Linden Thomas Advisory Services LLC raised its holdings in Xencor by 1.6% in the second quarter. Linden Thomas Advisory Services LLC now owns 43,643 shares of the biopharmaceutical company's stock valued at $826,000 after buying an additional 699 shares during the period. Baillie Gifford & Co. raised its stake in shares of Xencor by 3.3% in the 2nd quarter. Baillie Gifford & Co. now owns 23,530 shares of the biopharmaceutical company's stock valued at $445,000 after acquiring an additional 744 shares during the period. Louisiana State Employees Retirement System lifted its holdings in shares of Xencor by 3.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the biopharmaceutical company's stock valued at $587,000 after acquiring an additional 900 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its position in Xencor by 8.5% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 12,156 shares of the biopharmaceutical company's stock worth $244,000 after purchasing an additional 949 shares during the period. Finally, Diversified Trust Co boosted its position in Xencor by 7.8% during the 2nd quarter. Diversified Trust Co now owns 14,076 shares of the biopharmaceutical company's stock worth $266,000 after purchasing an additional 1,017 shares during the period.

Xencor Price Performance

Shares of XNCR stock traded up $0.09 during midday trading on Wednesday, reaching $23.72. 109,775 shares of the company traded hands, compared to its average volume of 604,000. The firm's 50 day simple moving average is $21.28 and its two-hundred day simple moving average is $20.37. The firm has a market cap of $1.66 billion, a PE ratio of -7.41 and a beta of 0.66. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. Xencor has a 1-year low of $15.31 and a 1-year high of $26.84.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.27. The firm had revenue of $10.70 million during the quarter, compared to analysts' expectations of $14.59 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. Xencor's revenue was down 81.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.40) earnings per share. On average, equities research analysts expect that Xencor will post -3.79 EPS for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.